<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286806</url>
  </required_header>
  <id_info>
    <org_study_id>AT-101-CS-006</org_study_id>
    <nct_id>NCT00286806</nct_id>
  </id_info>
  <brief_title>A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascenta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascenta Therapeutics</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of
      single-agent AT-101 in men with hormone-refractory prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete or partial remission of disease</measure>
  </secondary_outcome>
  <enrollment>27</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-101</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Rising PSA, as defined by increasing levels on at least two consecutive assessments

          2. ECOG performance status 0 or 1

          3. Adequate hematologic function

          4. Adequate liver and renal function

          5. Able to swallow and retain oral medication.

        Exclusion Criteria:

          1. Received prior chemotherapy for HRPC.

          2. Concurrent therapy for the treatment of prostate cancer.

          3. Clinical signs or symptoms of CNS metastases

          4. Requirement for corticosteroid treatment, with the exception of topical
             corticosteroids or inhaled corticosteroids for reactive airway disease.

          5. Active secondary malignancy or history of other malignancy within the last 5 years.

          6. Failure to recover from toxicities related to prior therapy.

          7. Uncontrolled concurrent illness.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance Leopold, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ascenta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <disposition_first_submitted>August 12, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 12, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 17, 2010</disposition_first_posted>
  <last_update_submitted>August 20, 2010</last_update_submitted>
  <last_update_submitted_qc>August 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Gossypol acetic acid</mesh_term>
    <mesh_term>Gossypol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

